Plus Therapeutics Stock Buy Hold or Sell Recommendation
| PSTV Stock | USD 0.68 0.07 9.33% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Plus Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Plus Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Plus Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Plus Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide. Note, we conduct extensive research on individual companies such as Plus and provide practical buy, sell, or hold advice based on investors' constraints. Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Plus |
Execute Plus Therapeutics Buy or Sell Advice
The Plus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Plus Therapeutics. Macroaxis does not own or have any residual interests in Plus Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Plus Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Plus Therapeutics Trading Alerts and Improvement Suggestions
| Plus Therapeutics is way too risky over 90 days horizon | |
| Plus Therapeutics has some characteristics of a very speculative penny stock | |
| Plus Therapeutics appears to be risky and price may revert if volatility continues | |
| Plus Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (13.32 M) with loss before overhead, payroll, taxes, and interest of (5.46 M). | |
| Plus Therapeutics currently holds about 20.27 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Plus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Plus Therapeutics, Inc. Short Interest Up 134.4 percent in February |
Plus Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Plus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Plus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Plus Therapeutics Returns Distribution Density
The distribution of Plus Therapeutics' historical returns is an attempt to chart the uncertainty of Plus Therapeutics' future price movements. The chart of the probability distribution of Plus Therapeutics daily returns describes the distribution of returns around its average expected value. We use Plus Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Plus Therapeutics returns is essential to provide solid investment advice for Plus Therapeutics.
| Mean Return | 2.46 | Value At Risk | -19.11 | Potential Upside | 10.10 | Standard Deviation | 40.01 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Plus Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Plus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Plus Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Plus Therapeutics back and forth among themselves.
| Shares | Ubs Group Ag | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Aigh Capital Management, Llc | 2024-12-31 | 560.9 K | Geode Capital Management, Llc | 2024-12-31 | 58.1 K | Vanguard Group Inc | 2024-12-31 | 32.5 K | Two Sigma Securities, Llc | 2024-12-31 | 14.6 K | Blackrock Inc | 2024-12-31 | 7 K | Tower Research Capital Llc | 2024-12-31 | 4.8 K | Advisor Group Holdings, Inc. | 2024-12-31 | 133 | Sbi Securities Co Ltd | 2024-12-31 | 66.0 | Bank Of America Corp | 2024-12-31 | 48.0 |
Plus Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (9.2M) | 10.1M | (280K) | (9.6M) | (8.6M) | (8.2M) | |
| Free Cash Flow | (8.9M) | (10.4M) | (13.5M) | (13.0M) | (11.7M) | (12.3M) | |
| Other Non Cash Items | 1.4M | 820K | 481K | 384K | 345.6K | 362.9K | |
| Net Income | (8.2M) | (13.4M) | (20.3M) | (13.3M) | (12.0M) | (12.6M) | |
| End Period Cash Flow | 8.3M | 18.4M | 18.1M | 8.6M | 9.8M | 14.5M | |
| Depreciation | 366K | 395K | 619K | 628K | 565.2K | 963.0K | |
| Net Borrowings | (3.7M) | (5.3M) | (276K) | (1.6M) | (1.8M) | (1.9M) | |
| Change To Netincome | 3.2M | (1.3M) | 940K | 605K | 544.5K | 517.3K | |
| Investments | (493K) | (82K) | (759K) | (160K) | (144K) | (136.8K) |
Plus Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Plus Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Plus Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Plus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 2.40 | |
β | Beta against Dow Jones | -0.35 | |
σ | Overall volatility | 41.97 | |
Ir | Information ratio | 0.06 |
Plus Therapeutics Volatility Alert
Plus Therapeutics is showing large volatility of returns over the selected time horizon. Plus Therapeutics is a potential penny stock. Although Plus Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Plus Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Plus instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Plus Therapeutics Fundamentals Vs Peers
Comparing Plus Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Plus Therapeutics' direct or indirect competition across all of the common fundamentals between Plus Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Plus Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Plus Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Plus Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Plus Therapeutics to competition |
| Fundamentals | Plus Therapeutics | Peer Average |
| Return On Equity | -5.22 | -0.31 |
| Return On Asset | -0.9 | -0.14 |
| Profit Margin | (2.25) % | (1.27) % |
| Operating Margin | (2.61) % | (5.51) % |
| Current Valuation | 5.75 M | 16.62 B |
| Shares Outstanding | 5.9 M | 571.82 M |
| Shares Owned By Insiders | 2.34 % | 10.09 % |
| Shares Owned By Institutions | 11.50 % | 39.21 % |
| Number Of Shares Shorted | 59.85 K | 4.71 M |
| Price To Book | 3.76 X | 9.51 X |
| Price To Sales | 0.77 X | 11.42 X |
| Revenue | 4.91 M | 9.43 B |
| Gross Profit | (5.46 M) | 27.38 B |
| EBITDA | (12.69 M) | 3.9 B |
| Net Income | (13.32 M) | 570.98 M |
| Cash And Equivalents | 20.27 M | 2.7 B |
| Cash Per Share | 0.60 X | 5.01 X |
| Total Debt | 4.18 M | 5.32 B |
| Debt To Equity | 0.53 % | 48.70 % |
| Current Ratio | 2.81 X | 2.16 X |
| Book Value Per Share | (0.88) X | 1.93 K |
| Cash Flow From Operations | (12.85 M) | 971.22 M |
| Short Ratio | 1.23 X | 4.00 X |
| Earnings Per Share | (2.37) X | 3.12 X |
| Target Price | 15.75 | |
| Number Of Employees | 20 | 18.84 K |
| Beta | 0.73 | -0.15 |
| Market Capitalization | 4.42 M | 19.03 B |
| Total Asset | 11.39 M | 29.47 B |
| Retained Earnings | (480.5 M) | 9.33 B |
| Working Capital | (893 K) | 1.48 B |
| Net Asset | 11.39 M |
Note: Acquisition by Petersen Greg of 3650 shares of Plus Therapeutics at 1.26 subject to Rule 16b-3 [view details]
Plus Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Plus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 404735.0 | |||
| Daily Balance Of Power | (0.58) | |||
| Rate Of Daily Change | 0.91 | |||
| Day Median Price | 0.66 | |||
| Day Typical Price | 0.67 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.07) |
About Plus Therapeutics Buy or Sell Advice
When is the right time to buy or sell Plus Therapeutics? Buying financial instruments such as Plus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Plus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Measuring and Control Equipment Thematic Idea Now
Measuring and Control Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Measuring and Control Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Measuring and Control Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.